title: Making Targeted Therapy Compatible with Checkpoint Immunotherapy.
abstract: Immune checkpoint blockades induced by antibodies are revolutionizing cancer therapy. Combinations of checkpoint immunotherapies with kinase inhibitors (KIs) are being clinically evaluated as oncogenic mutations arise. Off-target KI cross-reactivity will often compromise synergistic efficacy, with KIs suppressing T-cell functionalities that checkpoint blockers are purportedly boosting. This incompatibility may be removed through molecular optimization.
authors.affiliation: CONICET - National Research Council, INQUISUR - Chemistry Institute, Bahía Blanca 8000 and IAM - Argentine Institute of Mathematics, Buenos Aires 1083, Argentina; AF Innovation Consultancy, Avenida del Libertador 1092, Buenos Aires 1112, Argentina. Electronic address: ariel@afinnovation.com.
authors.forename: Ariel
authors.initials: A
authors.lastname: Fernández
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D047428:Protein Kinase Inhibitors